238 related articles for article (PubMed ID: 11584824)
1. Case 6: benefits and risks of OKT3 treatment in renal transplantation.
First MR
Transplantation; 2001 Sep; 72(6):1177-8. PubMed ID: 11584824
[No Abstract] [Full Text] [Related]
2. Treatment of steroid resistant rejection following renal transplantation: benefits and risks of OKT3 therapy.
Kehinde EO; Feehally J; Scriven SD; Veitch PS; Bell PR
Transplant Proc; 1996 Jun; 28(3):1449-50. PubMed ID: 8658735
[No Abstract] [Full Text] [Related]
3. Comparison of T10Bg.1A-31 and OKT3 in treating acute renal allograft rejection.
Lucas BA; Waid TH; Thompson JS; Brown SA; Munch LC; McKeown JW; Kryscio RJ; Prebeck RJ
Transplant Proc; 1993 Feb; 25(1 Pt 1):543-5. PubMed ID: 8438406
[No Abstract] [Full Text] [Related]
4. OKT3 treatment for steroid-resistant acute rejection in kidney transplantation.
Sevmis S; Emiroglu R; Karakayali F; Yagmurdur MC; Dalgic A; Moray G; Haberal M
Transplant Proc; 2005 Sep; 37(7):3016-8. PubMed ID: 16213290
[TBL] [Abstract][Full Text] [Related]
5. One center's experience with OKT3 in renal transplantation: patient and graft survival, complications, and cost analysis.
Güz G; Emiroğlu R; Demirhan B; Köseoğlu F; Karakayali H; Bilgin N
Transplant Proc; 2000 May; 32(3):572-3. PubMed ID: 10812117
[No Abstract] [Full Text] [Related]
6. Successful infliximab treatment of steroid and OKT3 refractory acute cellular rejection in two patients after intestinal transplantation.
Pascher A; Radke C; Dignass A; Schulz RJ; Veltzke-Schlieker W; Adler A; Sauer IM; Platz K; Klupp J; Volk HD; Neuhaus P; Mueller AR
Transplantation; 2003 Aug; 76(3):615-8. PubMed ID: 12923454
[TBL] [Abstract][Full Text] [Related]
7. Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab.
Alausa M; Almagro U; Siddiqi N; Zuiderweg R; Medipalli R; Hariharan S
Clin Transplant; 2005 Feb; 19(1):137-40. PubMed ID: 15659147
[TBL] [Abstract][Full Text] [Related]
8. [Neurologic complications induced by the treatment of the acute renal allograft rejection with the monoclonal antibody OKT3].
Fernández O; Romero F; Bravo M; Burgos D; Cabello M; González-Molina M
Neurologia; 1993 Oct; 8(8):277-80. PubMed ID: 8240843
[TBL] [Abstract][Full Text] [Related]
9. Treatment of steroid resistant acute rejection after renal transplantation.
Oh CK; Kim YS; Kim MS; Kim SI; Park K
Transplant Proc; 1996 Jun; 28(3):1453-4. PubMed ID: 8658737
[No Abstract] [Full Text] [Related]
10. The reuse of OKT3 after previous rejection or induction therapy in cadaveric renal transplantation.
Shield CF; Hughes JD
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):35-8. PubMed ID: 2510509
[TBL] [Abstract][Full Text] [Related]
11. [OKT3 treatment of refractory renal allograft rejection].
Xu J; Ma J; Bai X
Zhonghua Wai Ke Za Zhi; 1997 Apr; 35(4):223-5. PubMed ID: 10374543
[TBL] [Abstract][Full Text] [Related]
12. OKT3 in renal allografts: survival and complications.
D'Souza RJ; Kwan JT; Chang R; Bending MR
Clin Nephrol; 1999 Apr; 51(4):257-8. PubMed ID: 10230561
[No Abstract] [Full Text] [Related]
13. Visual loss complicating OKT3 monoclonal antibody therapy in a renal transplant recipient.
Jin DC; Kim SY; Lee JM; Koo WS; Choi EJ; Yoon YS; Bang BK
Nephrol Dial Transplant; 1995 Nov; 10(11):2144-6. PubMed ID: 8643188
[No Abstract] [Full Text] [Related]
14. Prolonged neurological disability following OKT3 therapy for acute renal transplant rejection.
Jeffrey RF; Johnson MH; Bamford JM; Giles GR; Brownjohn AM; Will EJ
Transplantation; 1993 Mar; 55(3):677-9. PubMed ID: 8456493
[No Abstract] [Full Text] [Related]
15. New insights into therapy with monoclonal antibodies in allograft transplantation.
Schena FP
Nephrol Dial Transplant; 1997; 12 Suppl 1():55-8. PubMed ID: 9075230
[No Abstract] [Full Text] [Related]
16. The influence of the immunosuppressants OKT3 and ATG on immunological parameters.
Neumann MC; Müller TF; Sprenger H; Gemsa D; Lange H
Clin Nephrol; 1996 May; 45(5):345-8. PubMed ID: 8738669
[TBL] [Abstract][Full Text] [Related]
17. [OKT3 for recipients with steroid-resistant acute rejection after liver transplantation].
Wu LW; He XS; Zhu XF; Wang DP; Ju WQ; Tai Q; Huang JF
Zhonghua Gan Zang Bing Za Zhi; 2007 Nov; 15(11):857-8. PubMed ID: 18073076
[No Abstract] [Full Text] [Related]
18. Orthoclone OKT3 treatment of acute renal allograft rejection.
Friedman J; Barnes L; Sheahan M; Tsai H; Goldstein G
Transplant Proc; 1987 Apr; 19(2 Suppl 2):46. PubMed ID: 3105144
[No Abstract] [Full Text] [Related]
19. Acute renal allograft rejection: the role of monoclonal antibodies in treatment: experience with orthoclonal anti-T3 cell antibody.
McLigeyo SO; Notghi A; Anderton JL; Dick J
East Afr Med J; 1990 Sep; 67(9):667-73. PubMed ID: 2123786
[TBL] [Abstract][Full Text] [Related]
20. Delayed use of OKT3 for severe acute tubular necrosis in renal transplantation.
VanderWerf BA
Transplant Proc; 1996 Aug; 28(4):2115-6. PubMed ID: 8769172
[No Abstract] [Full Text] [Related]
[Next] [New Search]
